168 related articles for article (PubMed ID: 34934147)
1. CD99 antibody disrupts T-cell acute lymphoblastic leukemia adhesion to meningeal cells and attenuates chemoresistance.
Ebadi M; Jonart LM; Ostergaard J; Gordon PM
Sci Rep; 2021 Dec; 11(1):24374. PubMed ID: 34934147
[TBL] [Abstract][Full Text] [Related]
2. CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
Jonart LM; Ostergaard J; Brooks A; Fitzpatrick G; Chen L; Gordon PM
Br J Haematol; 2023 May; 201(3):459-469. PubMed ID: 36535585
[TBL] [Abstract][Full Text] [Related]
3. Disrupting the leukemia niche in the central nervous system attenuates leukemia chemoresistance.
Jonart LM; Ebadi M; Basile P; Johnson K; Makori J; Gordon PM
Haematologica; 2020 Aug; 105(8):2130-2140. PubMed ID: 31624109
[TBL] [Abstract][Full Text] [Related]
4. High-valency Anti-CD99 Antibodies Toward the Treatment of T Cell Acute Lymphoblastic Leukemia.
Romero LA; Hattori T; Ali MAE; Ketavarapu G; Koide A; Park CY; Koide S
J Mol Biol; 2022 Mar; 434(5):167402. PubMed ID: 34958778
[TBL] [Abstract][Full Text] [Related]
5. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
Shi J; Zhang Z; Cen H; Wu H; Zhang S; Liu J; Leng Y; Ren A; Liu X; Zhang Z; Tong X; Liang J; Li Z; Zhou F; Huang L; Qin Y; Yang K; Zhang T; Zhu H
J Hematol Oncol; 2021 Oct; 14(1):162. PubMed ID: 34627328
[TBL] [Abstract][Full Text] [Related]
6. Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia.
Cox CV; Diamanti P; Moppett JP; Blair A
PLoS One; 2016; 11(10):e0165210. PubMed ID: 27764235
[TBL] [Abstract][Full Text] [Related]
7. Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells.
Wang J; Liu X; Qiu Y; Shi Y; Cai J; Wang B; Wei X; Ke Q; Sui X; Wang Y; Huang Y; Li H; Wang T; Lin R; Liu Q; Xiang AP
J Hematol Oncol; 2018 Jan; 11(1):11. PubMed ID: 29357914
[TBL] [Abstract][Full Text] [Related]
8. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
Tavakkoli M; Chung SS; Park CY
Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
[TBL] [Abstract][Full Text] [Related]
9. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
10. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.
Habiel DM; Krepostman N; Lilly M; Cavassani K; Coelho AL; Shibata T; Elenitoba-Johnson K; Hogaboam CM
Oncotarget; 2016 Dec; 7(50):83514-83529. PubMed ID: 27835864
[TBL] [Abstract][Full Text] [Related]
11. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Morra E; Lazzarino M; Inverardi D; Brusamolino E; Orlandi E; Canevari A; Pagnucco G; Bernasconi C
J Clin Oncol; 1986 Aug; 4(8):1207-11. PubMed ID: 3461134
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
[TBL] [Abstract][Full Text] [Related]
13. The CNS microenvironment promotes leukemia cell survival by disrupting tumor suppression and cell cycle regulation in pediatric T-cell acute lymphoblastic leukemia.
Enlund S; Sinha I; Neofytou C; Amor AR; Papadakis K; Nilsson A; Jiang Q; Hermanson O; Holm F
Exp Cell Res; 2024 Apr; 437(2):114015. PubMed ID: 38561062
[TBL] [Abstract][Full Text] [Related]
14. Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia.
Berrazouane S; Boisvert M; Salti S; Mourad W; Al-Daccak R; Barabé F; Aoudjit F
Cell Death Dis; 2019 May; 10(5):357. PubMed ID: 31043590
[TBL] [Abstract][Full Text] [Related]
15. A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors.
Sharma A; Gadkari RA; Ramakanth SV; Padmanabhan K; Madhumathi DS; Devi L; Appaji L; Aster JC; Rangarajan A; Dighe RR
Sci Rep; 2015 Jun; 5():11012. PubMed ID: 26046801
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
[TBL] [Abstract][Full Text] [Related]
17. Triggering of CD99 on monocytes by a specific monoclonal antibody regulates T cell activation.
Laopajon W; Pata S; Takheaw N; Surinkaew S; Khummuang S; Kasinrerk W
Cell Immunol; 2019 Jan; 335():51-58. PubMed ID: 30396687
[TBL] [Abstract][Full Text] [Related]
18. TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia.
Chu M; Yin K; Dong Y; Wang P; Xue Y; Zhou P; Wang Y; Wang Y
Oncotarget; 2017 Jan; 8(1):1405-1415. PubMed ID: 27902457
[TBL] [Abstract][Full Text] [Related]
19. Cell Adhesion Molecule CD99 in Cancer Immunotherapy.
Yu F; Liu G; Zhang H; Wang X; Wu Z; Xu Q; Wu Y; Chen D
Curr Mol Med; 2023; 23(10):1028-1036. PubMed ID: 36214301
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib combined with chemotherapy can eradicate chemorefractory central nervous system acute lymphoblastic leukaemia.
Ebadi M; Wasko J; Weisdorf DJ; Gordon PM; Rashidi A
Br J Haematol; 2019 Oct; 187(1):e24-e27. PubMed ID: 31385290
[No Abstract] [Full Text] [Related]
[Next] [New Search]
